EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS).
NeuroSense Therapeutics Ltd.（納斯達克股票代碼：NRSN）週三表示，目前正在與幾家千億級藥品公司進行高級討論，就開發和商業化其領先藥物候選PrimeC用於肌萎縮側索硬化（ALS）的潛在戰略合作伙伴關係進行討論。
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement.
這些基於非約束條款的討論表明，NeuroSense可能獲得豐厚的經濟利益，包括預付款、里程碑付款和版稅付款作爲協議的一部分。
NeuroSense anticipates receiving terms from these discussions in the fourth quarter of 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what the final terms would be, if any, or that a definitive agreement will be reached.
NeuroSense預計將在2024年第四季度收到來自這些討論的條款；然而，並不能保證與任何藥品公司達成最終的條款，也不能確定達成一項明確協議的時間、最終的條款（如果有的話）將是什麼。
In August, NeuroSense Therapeutics released 12-month iron biomarker data from its PARADIGM Phase 2b study for PrimeC in ALS patients.
在8月，NeuroSense Therapeutics發佈了PARADIGm第20億期PrimeC在ALS患者中的12個月鐵生物標誌物數據。
The results demonstrated the target engagement of PrimeC in iron regulation, which is linked to disease mitigation and improved survival.
結果顯示了PrimeC在鐵調節中的目標作用，這與疾病緩解和生存率的提高有關。
These changes in iron metabolism align with improved clinical outcomes. Patients on PrimeC maintained better functionality and survival rates than those on placebo.
鐵代謝的這些變化與臨床結果的改善相一致。接受PrimeC治療的患者比安慰劑組的患者保持更好的功能和生存率。
In July, 12-month data of the PARADIGM Phase 2b study showed a significant improvement in the rate of decline of ALS Functional Rating Scale-Revised scores and survival rates for subjects who received PrimeC from the start of the trial compared to those who started on placebo.
7月，PARADIGm第20億期研究的12個月數據顯示，在開始試驗時接受PrimeC的受試對象與接受安慰劑的受試對象相比，ALS功能評定量表-修訂版得分下降的速度有顯著改善，生存率也有所提高。
Specifically, the intent to treat analysis at 12 months revealed a difference of 6.5 points in the ALSFRS-R, representing a 36% improvement and a statistically significant P value of 0.009.
具體而言，12個月意向治療分析顯示ALSFRS-R的差異爲6.5分，表示改善了36%，P值達到顯著水平（0.009）。
In addition, at 12 months, participants on PrimeC demonstrated 43% better survival than those initially on placebo.
此外，在12個月的時間內，PrimeC參與者的生存率比最初使用安慰劑的參與者高出43%。
Additional results from the PARADIGM Phase 2b study showed a complication-free survival revealed a 57% difference in favor of PrimeC over placebo after 12 months of treatment in the Intent to Treat population and demonstrated an outcome of 73% (p=0.02) difference in favor of PrimeC over placebo after 12 months of treatment in the pre-defined Per Protocol Population.
PARADIGm Phase 20億研究的附加結果顯示，在意向治療人群中，PrimeC與安慰劑相比，在治療12個月後，無併發症的生存率有57%的差異，而在預先確定的嚴格執行人群中，PrimeC與安慰劑相比，在治療12個月後的結果達到73%的差異（p=0.02）。
Price Action: NRSN stock closed at $0.74 on Tuesday.
股票價格: NRSN股票週二收盤價爲0.74美元。
- Why Is Clinical Diagnostics Focused Trinity Biotech Stock Trading Higher On Tuesday?
- 爲什麼在週二臨床診斷專注的Trinity Biotech股票交易上漲？
譯文內容由第三人軟體翻譯。